152 related articles for article (PubMed ID: 21035497)
1. Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways.
Jhanwar-Uniyal M; Albert L; McKenna E; Karsy M; Rajdev P; Braun A; Murali R
Adv Enzyme Regul; 2011; 51(1):164-70. PubMed ID: 21035497
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497
[TBL] [Abstract][Full Text] [Related]
3. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
4. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
5. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
Goc A; Al-Husein B; Kochuparambil ST; Liu J; Heston WW; Somanath PR
Int J Oncol; 2011 Jan; 38(1):267-77. PubMed ID: 21109949
[TBL] [Abstract][Full Text] [Related]
6. PI3K-Akt-mTOR and MAPK signaling pathways in polycystic ovarian syndrome, uterine leiomyomas and endometriosis: an update.
Makker A; Goel MM; Das V; Agarwal A
Gynecol Endocrinol; 2012 Mar; 28(3):175-81. PubMed ID: 21916800
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
8. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
10. Role of the phosphoinositide 3-kinase-Akt-mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat medial prefrontal cortex.
Sui L; Wang J; Li BM
Learn Mem; 2008 Oct; 15(10):762-76. PubMed ID: 18832563
[TBL] [Abstract][Full Text] [Related]
11. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
12. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells.
Martelli AM; Evangelisti C; Follo MY; Ramazzotti G; Fini M; Giardino R; Manzoli L; McCubrey JA; Cocco L
Curr Med Chem; 2011; 18(18):2715-26. PubMed ID: 21649579
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme.
Albert L; Karsy M; Murali R; Jhanwar-Uniyal M
Cancer Genomics Proteomics; 2009; 6(5):255-61. PubMed ID: 19996130
[TBL] [Abstract][Full Text] [Related]
14. The PI3K/Akt/mTOR pathway mediates retinal progenitor cell survival under hypoxic and superoxide stress.
Sanghera KP; Mathalone N; Baigi R; Panov E; Wang D; Zhao X; Hsu H; Wang H; Tropepe V; Ward M; Boyd SR
Mol Cell Neurosci; 2011 Jun; 47(2):145-53. PubMed ID: 21463685
[TBL] [Abstract][Full Text] [Related]
15. The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin.
Stylianou K; Petrakis I; Mavroeidi V; Stratakis S; Vardaki E; Perakis K; Stratigis S; Passam A; Papadogiorgaki E; Giannakakis K; Nakopoulou L; Daphnis E
Nephrol Dial Transplant; 2011 Feb; 26(2):498-508. PubMed ID: 20709738
[TBL] [Abstract][Full Text] [Related]
16. Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells.
Marfe G; Di Stefano C; Gambacurta A; Ottone T; Martini V; Abruzzese E; Mologni L; Sinibaldi-Salimei P; de Fabritis P; Gambacorti-Passerini C; Amadori S; Birge RB
Exp Hematol; 2011 Jun; 39(6):653-665.e6. PubMed ID: 21392556
[TBL] [Abstract][Full Text] [Related]
17. Role of hypoxia-induced fibronectin-integrin β1 expression in embryonic stem cell proliferation and migration: Involvement of PI3K/Akt and FAK.
Lee SH; Lee YJ; Han HJ
J Cell Physiol; 2011 Feb; 226(2):484-93. PubMed ID: 20677223
[TBL] [Abstract][Full Text] [Related]
18. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.
Georgakis GV; Younes A
Expert Rev Anticancer Ther; 2006 Jan; 6(1):131-40. PubMed ID: 16375650
[TBL] [Abstract][Full Text] [Related]
19. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
[TBL] [Abstract][Full Text] [Related]
20. Multiple signal pathways in obesity-associated cancer.
Chen J
Obes Rev; 2011 Dec; 12(12):1063-70. PubMed ID: 22093240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]